Press Release Details

CHENGDU, China, March 03, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced its participation in three upcoming investor conferences. Details of the conferences and management participation are as follows:   

25th Credit Suisse Asian Investment Conference (Virtual)
One-on-one and small group meetings: March 21-30, 2022
Participants: Management team and IR
For more information, please contact your Credit Suisse representative.

Morgan Stanley 2022 Hong Kong Summit (Virtual)
One-on-one and small group meetings: March 22-24, 2022
Participants: Management team and IR
For more information, please contact your Morgan Stanley representative.

21st Annual Needham Virtual Healthcare Conference (Virtual)
One-on-one and small group meetings: April 11-14, 2022
Participants: Management team and IR
For more information, please contact your Needham representative.

About Clover Biopharmaceuticals 
Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2. 

For more information, please visit Clover’s website: www.cloverbiopharma.com and follow the company on LinkedIn.

Clover Forward-looking Statements 
This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. 

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement. 

Clover Biopharmaceuticals:

Cindy Min 
SVP, Public Affairs 
media@cloverbiopharma.com 

Naomi Eichenbaum 
VP, Investor Relations 
investors@cloverbiopharma.com